Savara Inc (SVRA)
1.68
-0.03 (-1.75%)
USD |
NASDAQ |
Aug 15, 16:00
1.69
+0.01 (+0.60%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 191.59M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 41.18% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.508 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.44% |
News
Headline
Wire
Time (ET)
Yahoo
07/11 08:05
MT Newswires
06/16 10:27
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/11/2022* | -- | Results | Q3 2022 | -- | -0.07 | -- | |
| 08/11/2022 | -- | Results | Q2 2022 | -0.06 | -0.06 | 0.00% | |
| 05/11/2022 | -- | Results | Q1 2022 | -0.05 | -0.08 | 37.50% | |
| 03/30/2022 | -- | Results | Q4 2021 | -0.07 | -0.07 | -3.70% | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.07 | -0.09 | 25.53% | |
| 08/12/2021 | -- | Results | Q2 2021 | -0.07 | -0.12 | 41.67% | |
| 05/13/2021 | -- | Results | Q1 2021 | -0.13 | -0.10 | -36.84% | |
| 11/05/2020 | -- | Results | Q3 2020 | -0.18 | -0.21 | 12.20% |
*Estimated Date/Time
Earnings
Profile
Edit
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
| URL | https://www.savarapharma.com |
| Investor Relations URL | https://savarapharma.com/investors/events-presentations/ |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 11, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 15, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 37.61M |
| Net Income (TTM) | -39.32M |
| Total Assets (Quarterly) | 156.78M |
| Total Liabilities (Quarterly) | 29.74M |
| Shareholders Equity (Quarterly) | 127.04M |
| Cash from Operations (TTM) | -36.03M |
| Cash from Investing (TTM) | 90.58M |
| Cash from Financing (TTM) | 0.103M |
Ratings
Profile
Edit
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
| URL | https://www.savarapharma.com |
| Investor Relations URL | https://savarapharma.com/investors/events-presentations/ |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 11, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SVRA Tweets |